A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection

Inclusion Criteria: * Screening laboratory result indicating HCV Genotype 2, 3, 4, 5, or 6 infection. * Chronic HCV infection. * Participant had to be either HCV treatment-naïve or treatment-experienced. * Participant had to be documented as non-cirrhotic or as having compensated cirrhosis (GT3 only). Exclusion Criteria: * History of severe, life-threatening or other significant sensitivity to any drug. * Female who was pregnant, planning to become pregnant during the study, or breastfeeding; or male whose partner was pregnant or planning to become pregnant during the study. * Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol in the opinion of the investigator. * Positive test result at Screening for hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus antibody (HIV Ab). * HCV genotype performed during screening indicating co-infection with more than one HCV genotype.